NO20030658D0 - Modulation of multiple lineage kinase proteins - Google Patents

Modulation of multiple lineage kinase proteins

Info

Publication number
NO20030658D0
NO20030658D0 NO20030658A NO20030658A NO20030658D0 NO 20030658 D0 NO20030658 D0 NO 20030658D0 NO 20030658 A NO20030658 A NO 20030658A NO 20030658 A NO20030658 A NO 20030658A NO 20030658 D0 NO20030658 D0 NO 20030658D0
Authority
NO
Norway
Prior art keywords
modulation
kinase proteins
lineage kinase
multiple lineage
proteins
Prior art date
Application number
NO20030658A
Other languages
Norwegian (no)
Other versions
NO20030658L (en
Inventor
Anna Maroney
Kevin M Walton
Craig A Dionne
Nicola Neff
Jr Ernest Knight
Marcie A Glicksman
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20030658D0 publication Critical patent/NO20030658D0/en
Publication of NO20030658L publication Critical patent/NO20030658L/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
NO20030658A 2000-08-11 2003-02-10 Method for Modeling Multiple Lineage Kinase Proteins and Investigation of Compounds Modulating Multiple Lineage Kinase Proteins NO20030658L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63705400A 2000-08-11 2000-08-11
PCT/US2001/024822 WO2002014536A2 (en) 2000-08-11 2001-08-08 Odulating multiple lineage kinase proteins

Publications (2)

Publication Number Publication Date
NO20030658D0 true NO20030658D0 (en) 2003-02-10
NO20030658L NO20030658L (en) 2003-04-09

Family

ID=24554347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030658A NO20030658L (en) 2000-08-11 2003-02-10 Method for Modeling Multiple Lineage Kinase Proteins and Investigation of Compounds Modulating Multiple Lineage Kinase Proteins

Country Status (19)

Country Link
EP (1) EP1309721A2 (en)
JP (1) JP2005503102A (en)
CN (1) CN1458979A (en)
AU (2) AU8317901A (en)
BG (1) BG107623A (en)
BR (1) BR0113266A (en)
CA (1) CA2419985A1 (en)
CZ (1) CZ2003680A3 (en)
HR (1) HRP20030162A2 (en)
HU (1) HUP0501110A3 (en)
IL (1) IL154311A0 (en)
IS (1) IS6711A (en)
MX (1) MXPA03001218A (en)
NO (1) NO20030658L (en)
NZ (1) NZ524034A (en)
PL (1) PL366248A1 (en)
SK (1) SK2692003A3 (en)
WO (1) WO2002014536A2 (en)
ZA (1) ZA200301109B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
WO2005007144A2 (en) * 2003-07-14 2005-01-27 Decode Genetics Ehf Method of diagnosis and treatment for asthma based on haplotype association
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
WO2014172616A2 (en) * 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
BR112019009711A2 (en) * 2016-11-25 2019-08-13 Genuv Inc neuroregeneration induction method, neuron protection method against neuronal loss or damage, neurodegenerative disease prevention or treatment method due to neuronal loss or damage, and drug candidate screening method for the treatment of neurodegenerative disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
DK1105728T3 (en) * 1998-08-26 2005-08-08 Cephalon Inc Modulation of multiple lineage kinase proteins
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones

Also Published As

Publication number Publication date
ZA200301109B (en) 2004-07-20
EP1309721A2 (en) 2003-05-14
BR0113266A (en) 2005-01-04
BG107623A (en) 2003-11-28
CA2419985A1 (en) 2002-02-21
IL154311A0 (en) 2003-09-17
NZ524034A (en) 2006-11-30
SK2692003A3 (en) 2003-08-05
PL366248A1 (en) 2005-01-24
WO2002014536A2 (en) 2002-02-21
IS6711A (en) 2003-02-10
MXPA03001218A (en) 2003-05-27
CN1458979A (en) 2003-11-26
HRP20030162A2 (en) 2005-12-31
AU8317901A (en) 2002-02-25
WO2002014536A9 (en) 2003-12-18
HUP0501110A2 (en) 2006-03-28
JP2005503102A (en) 2005-02-03
AU2001283179B2 (en) 2006-07-13
WO2002014536A3 (en) 2003-01-30
CZ2003680A3 (en) 2003-11-12
NO20030658L (en) 2003-04-09
HUP0501110A3 (en) 2006-06-28

Similar Documents

Publication Publication Date Title
ATE411332T1 (en) 3'-PRODRUGS OF 2'-DEOXY-BETA-L-NUCLEOSIDES
ID29028A (en) PIROLOPIRIMIDINA AS A PROTEIN OF INHINING PROTEIN
DE60023268D1 (en) INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTS OF CYCLINES et IkB-alpha
NO995852L (en) New form of S-omeprazole
ATE349431T1 (en) PREPARATION OF AMINOPYRIMIDINE COMPOUNDS
NO20030443D0 (en) Process for the preparation of functional protein domains
NO20020185L (en) Formulations of IL-11
DE60019960D1 (en) PREPARATION OF ISOBUTENCOPOLYMERS
FR2779192B1 (en) COUPLING OF TREES
DE60038118D1 (en) FORMULATIONS OF GROWTH HORMONES
NO20023837L (en) Modulation of bone formation
DE60132362D1 (en) PREPARATION OF ULTRADÜNNWANDIGEN CORDIERIT STRUCTURES
DE60142051D1 (en) PREPARATION OF PERFLUOROLEFINES
NO20016151D0 (en) Preparation of substituted piperidin-4-ones
NO20030658D0 (en) Modulation of multiple lineage kinase proteins
DE69935165D1 (en) PREPARATION OF POLYOLEFIN
DE60007360T2 (en) AMORPHE MODIFICATION OF TORASEMID
NO20013795D0 (en) Regulation of anesthesia
DE60208365D1 (en) USE OF PYRIDOINDOLON DERIVATIVES FOR THE PREPARATION OF ANTICROBIAL AGENTS
DE69811864D1 (en) MANUFACTURE OF TAPE-WORKPIECES
ID22787A (en) NITRO-BENZAMIDA IS USED AS ANTI-ARRITIMIA
DE60004187D1 (en) MANUFACTURE OF POLYSULPHONES
DE60025363D1 (en) PREPARATION OF RHPBGD
DE60221998D1 (en) PREPARATION OF AMINONITRILES
ITMI20000810A0 (en) PROCEDURE FOR THE PREPARATION OF 5'-ACETYLSTAVUDINE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application